ISRG:NSD-Intuitive Surgical, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 973.89

Change

+28.95 (+3.06)%

Market Cap

USD 111.89B

Volume

0.61M

Avg Analyst Target

USD 881.12 (-9.53%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVCR NovoCure Limited

-0.07 (-0.04%)

USD19.65B 1,826.92 437.02
HOLX Hologic, Inc

+1.77 (+2.53%)

USD17.94B 9.61 6.88
MASI Masimo Corporation

+2.69 (+1.00%)

USD14.74B 68.00 49.19
XRAY DENTSPLY SIRONA Inc

-0.46 (-0.72%)

USD13.92B 81.02 25.48
RGEN Repligen Corporation

+2.41 (+1.18%)

USD11.18B 139.84 85.81
STAA STAAR Surgical Company

-0.93 (-0.69%)

USD6.31B 608.46 325.33
ICUI ICU Medical, Inc

-0.74 (-0.38%)

USD4.18B 45.52 18.75
ATRC AtriCure, Inc

+0.27 (+0.34%)

USD3.62B N/A N/A
MMSI Merit Medical Systems, Inc

+0.71 (+1.12%)

USD3.54B 843.87 32.26
BLFS BioLife Solutions, Inc

+0.61 (+1.33%)

USD1.86B 337.03 1,288.40

ETFs Containing ISRG

Symbol Name Weight Mer Price(Change) Market Cap
BOTZ Global X Robotics & Artif.. 0.00 % 0.68 %

-0.07 (-0.21%)

USD2.58B
RBOD:LSE iShares Automation & Robo.. 0.00 % 0.40 %

+0.06 (+0.71%)

USD0.14B
IROB:F Legal & General UCITS ETF.. 0.00 % 0.80 %

+0.11 (+0.48%)

USD1.23B
WELL:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.59 %

N/A

USD0.02B
ROBO:LSE L&G ROBO Global Robotics .. 0.00 % 0.80 %

+0.17 (+0.66%)

USD1.25B
ROBG:LSE Legal & General UCITS ETF.. 0.00 % 0.80 %

-2.50 (-0.13%)

USD1.24B
ROBE:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.13 (+0.61%)

USD1.24B
RBTX:LSE iShares IV Public Limited.. 0.00 % 0.40 %

+2.38 (+0.25%)

USD3.63B
RBOT:LSE iShares Automation & Robo.. 0.00 % 0.40 %

+0.10 (+0.77%)

USD3.80B
RBOT-U:CA Horizons Robotics and Aut.. 0.00 % 0.45 %

N/A

N/A
FTLS First Trust Long/Short Eq.. 0.00 % 1.55 %

+0.03 (+0.06%)

USD0.37B
RBOT:CA Horizons Robotics and Aut.. 0.00 % 0.59 %

+0.02 (+0.06%)

USD0.07B
ROBO Robo Global Robotics and .. 0.00 % 0.95 %

-0.05 (-0.08%)

USD1.84B
HIG:CA Brompton Global Healthcar.. 0.00 % 0.97 %

+0.08 (+0.76%)

USD0.05B
DXU:CA Dynamic Active U.S. Divid.. 0.00 % 0.80 %

+0.20 (+0.43%)

USD0.27B
DXG:CA Dynamic Active Global Div.. 0.00 % 0.81 %

+0.26 (+0.51%)

USD1.24B
RYH Invesco S&P 500 Equal Wei.. 0.00 % 0.40 %

+2.44 (+0.82%)

USD0.86B
ROBO Robo Global Robotics and .. 0.00 % 0.95 %

-0.05 (-0.08%)

USD1.84B
IHI iShares U.S. Medical Devi.. 0.00 % 0.42 %

+0.61 (+1.00%)

USD7.72B
IROB:XETRA Legal & General UCITS ETF.. 0.00 % 0.80 %

+0.12 (+0.55%)

USD1.23B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.04% 67% D+ 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.04% 67% D+ 68% D+
Trailing 12 Months  
Capital Gain 41.85% 50% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.85% 50% F 58% F
Trailing 5 Years  
Capital Gain 323.82% 62% D- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 323.82% 62% D- 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 35.56% 63% D 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.56% 63% D 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 26.35% 80% B- 65% D
Risk Adjusted Return 134.93% 87% B+ 98% A+
Market Capitalization 111.89B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 97.22 38% F 12% F
Price/Book Ratio 11.14 16% F 13% F
Price / Cash Flow Ratio 75.40 18% F 6% F
EV/EBITDA 67.24 26% F 14% F
Management Effectiveness  
Return on Equity 12.67% 79% C+ 79% C+
Return on Invested Capital 10.10% 70% C- 79% C+
Return on Assets 6.90% 75% C 88% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.07 58% F 41% F
Short Percent 1.18% 91% A- 74% C
Beta 1.05 61% D- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.